Leopold Zev, Passarelli Rachel, Mikhail Mark, Tabakin Alexandra, Chua Kevin, Ennis Ronald D, Nosher John, Singer Eric A
Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Department of Radiation Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
J Kidney Cancer VHL. 2022 Aug 15;9(3):5-23. doi: 10.15586/jkcvhl.v9i3.233. eCollection 2022.
While the gold-standard for management of localized renal cell carcinoma (RCC) is partial nephrectomy, recent ablative strategies are emerging as alternatives with comparable rates of complications and oncologic outcomes. Thermal ablation, in the form of radiofrequency ablation and cryoablation, is being increasingly accepted by professional societies, and is particularly recommended in patients with a significant comorbidity burden, renal impairment, old age, or in those unwilling to undergo surgery. Maturation of long-term oncologic outcomes has further allowed increased confidence in these management strategies. New and exciting ablation technologies such as microwave ablation, stereotactic body radiotherapy, and irreversible electroporation are emerging. In this article, we review the existing management options for localized RCC, with specific focus on the oncologic outcomes associated with the various ablation modalities.
虽然局限性肾细胞癌（RCC）管理的金标准是部分肾切除术，但最近的消融策略正在成为替代方案，其并发症发生率和肿瘤学结局相当。以射频消融和冷冻消融形式的热消融越来越被专业学会所接受，特别推荐给合并症负担重、肾功能损害、老年或不愿接受手术的患者。长期肿瘤学结局的成熟进一步增强了人们对这些管理策略的信心。新的、令人兴奋的消融技术，如微波消融、立体定向体部放疗和不可逆电穿孔正在出现。在本文中，我们回顾了局限性RCC的现有管理选择，特别关注与各种消融方式相关的肿瘤学结局。
